ClinicalTrials.gg
CompletedNCT01449370Updated Mar 9, 2017Results posted

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

A Phase 1 interventional study of TAK-117 in Metastatic Solid Tumors, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-09.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
125
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the maximum tolerated dose (MTD) and/or optimal biologic dose(OBD), safety and tolerability, dose-limiting toxicity (DLT) of TAK-117 when administered orally in subjects with advanced solid malignancies.

02

Conditions studied

  • Metastatic Solid Tumors

Browse trials for

Keywords

  • INK1117
  • PIK3CA
  • KINASE
  • TUMOR
  • CANCER
  • Locally advanced or metastatic solid tumors
  • not eligible for standard of care therapy
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 125 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.

First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects have had their PIK3CA gene mutation status assessed prior to enrolling into the study
  • Subjects must have documented disease progression prior to enrolling into the study
  • locally advanced or solid tumors with the exception of primary brain tumor, and have failed or are not eligible for standard of care therapy.
  • Age greater than or equal to (>=) 18 years, including males and females;
  • (ECOG) performance status (PS) 0-1;
  • Adequate organ function;
  • Male subjects must be surgically sterile or must agree to use physician-approved during the study and for 30 days following the last study drug administration;
  • Ability to swallow oral medications;
  • Ability to understand and willingness to sign prior to initiation of any study procedures;
  • For women of , negative serum pregnancy test within 14 days prior to the first study drug administration and use of physician-approved method of birth control from 30 days prior to the first study drug administration to 30 days following the last study drug administration

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of primary brain tumor; untreated or history of or spinal cord compression;
  • Received prior cancer or other therapy within 2 weeks prior to the first administration of study drug;
  • Have received a systemic within one week prior to the first administration of study drug;
  • cardiac disease;
  • Myocardial infarction or unstable angina within 6 months prior to the first administration of study drug;
  • Malabsorption ;
  • Poorly controlled diabetes mellitus;
  • Pregnancy (positive serum or urine pregnancy test) or breast feeding;
  • Untreated brain metastasis or history of leptomeningeal disease or spinal cord compression;
  • Failed to recover from the reversible effects of prior anticancer therapies;
  • Have received a selective phosphoinositide-3-kinase alpha isoform (PI3K-alpha) inhibitor
  • Other clinically significant co-morbidities, such as uncontrolled pulmonary disease, active central nervous system (CNS) disease, active infection, or any other condition that could compromise the subject's participation in the study
  • Known (HIV) infection
  • Have a secondary within the last 3 years prior to first dose of study drug, excluding treated non-melanoma skin cancer, carcinoma in situ, or locally-treated prostate cancer
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Arm A

    TAK-117 administered once a day orally

    Drug: TAK-117

  • Experimental
    Arm B

    TAK-117 administered orally intermittently, once every other day (Monday, Wednesday, and Friday) each week

    Drug: TAK-117

  • Experimental
    Arm C

    TAK-117 administered orally intermittently, once a day for 3 consecutive days (Monday, Tuesday, and Wednesday) each week

    Drug: TAK-117

Interventions

  • oral administration of TAK-117, daily and intermittent schedules.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of TAK-117

    MTD is highest dose level of TAK-117 at which no more than 1 out of 6 participants had a dose limiting toxicity (DLT) during first cycle. DLT was any 1 of following events occurring within first 21 days of Cycle 1 of TAK-117 administration, Grade 2: fasting hyperglycemia for \>14 days. Grade 3: nausea and/or vomiting/diarrhea for \>7 days; rash for \>7 days; thrombocytopenia with bleeding; fasting hyperglycemia for \>24 hours(hr). Grade \>=3:nonhematologic toxicity considered clinically significant by investigator. Grade 4:neutropenia (absolute neutrophil count \<=0.5\*10\^9per liter\[/L\]) for \>7 days in absence of growth factor support; neutropenia of any duration accompanied with fever \>=38.5 degree Celsius and/or systemic infection. Grade \>=4:hematologic toxicity. Inability to administer at least 75% of planned doses of TAK-117 within Cycle 1 due to its related toxicity;Any clinically significant occurrence that investigators and sponsor agreed would place participants at undue safety risk.

    Time frame: Baseline up to Cycle 1 Day 21

  2. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Death, Adverse Events (AEs) Leading to Discontinuation of Study Drug, and DLTs in Cycle 1

    Time frame: Baseline up to Cycle 27 Day 45

  3. Number of Participants With Highest Level of TEAEs Severity

    Severity of AEs was evaluated based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0 as follow: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (life-threatening); Grade 5 (fatal).

    Time frame: Baseline up to Cycle 27 Day 45

  4. Number of Participants With Clinically Meaningful Changes in Laboratory Values

    Time frame: Baseline up to Cycle 27 Day 45

  5. Number of Participants With Clinically Meaningful Changes in Vital Signs

    Time frame: Baseline up to Cycle 27 day 45

  6. Number of Participants With Clinically Meaningful Changes in Electrocardiogram (ECG)

    Time frame: Baseline up to Cycle 27 Day 45

Secondary outcomes

  1. Overall Response Rate (ORR)

    The estimate of the ORR is calculated as crude percentage of participants who's best overall response is complete response (CR) or partial response (PR). Objective response (CR and PR) as determined by the participants best tumor response was assessed using response evaluation criteria in solid tumors (RECIST) version 1.1. As per RECIST version 1.1, CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 millimeter \[mm\]). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease was defined as not qualifying for CR, PR, and progressive disease (PD).

    Time frame: Cycle 1 Day 8 up to Cycle 27 Day 1 or disease progression or death

  2. Duration of Objective Response

    Duration of response was to be calculated for participants who achieved CR or PR. Duration of objective response was defined as the number of days from the start date of PR or CR (whichever response was achieved first) to the first date that PD or disease progression was objectively documented. The duration of objective response was to be right-censored for participants who achieved CR or PR and met 1 of the following conditions: Non-protocol anticancer treatment started before documentation of PD; Documented PD after more than 1 missed disease assessment visit; Alive and did not have documentation of PD before a data analysis cutoff date.

    Time frame: Cycle 1 Day 8 up to Cycle 27 Day 1 or disease progression or death

  3. Clinical Benefit Rate (CBR)

    Clinical benefit rate was defined as the participants who achieved stable disease (SD) for at least 15 weeks, CR, or PR. The estimate of the CBR was calculated as crude percentage of participants whose best ORR was CR, PR or SD for at least 90 days.

    Time frame: Cycle 1 Day 8 up to Cycle 27 Day 1 or disease progression or death

  4. Cmax: Maximum Observed Plasma Concentration for TAK-117

    Time frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose

  5. Ctrough: Observed Concentration at the End of Dosing Interval for TAK-117

    Time frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose

  6. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-117

    Time frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose

  7. T 1/2z: Terminal Disposition Phase Half-life for TAK-117

    Time frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose

  8. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-117

    Time frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose

  9. AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-117

    Time frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose

  10. %AUC Extrapolated: Percentage of Area Under Concentration-extrapolated

    Time frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose

  11. Percent Change From Baseline in Pharmacodynamic Markers

    Pharmacodynamic markers included phosphorylated ribosomal protein S6 (PS6), phosphorylated eukaryotic initiation factor 4E-binding protein 1 (P4EBP1), phosphorylated N-myc downstream regulated gene 1 (PNDRG1), phosphorylated proline-rich AKT substrate of 40 kilodaltons (PPRAS40), and phosphorylated serine/threonine protein kinase AKT (PAKT). Analysis population (n) for each skin biopsy biomarker is as follow: P4EBP1 (n=6,6,6,2,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PAKT and PNDRG1 (n=6,6,7,2,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PPRAS40 (n= 6,0,6,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PS6 (n=6,6,7,2,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0)."n" for each tumor tissue biomarkers is as follow: P4EBP1, PAKT, PNDRG1, and PS6 (n=1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PPRAS40 (n= 1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0).

    Time frame: Cycle 1 Day 8

07

Results

Posted Mar 9, 2017

Participant flow

Participants took part in the study at 5 investigative sites in England, Spain and the United States from 06 October 2011 to 15 January 2016.

Participant flow — Overall Study
MilestoneProcess A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QW
Started6684333312333311337333644108
Completed0000000000000000000000000
Not completed6684333312333311337333644108
Withdrew: Disease progression5483333291332831431252373
Withdrew: Adverse event1201000011000201001101013
Withdrew: Participant decision0000000110001101301001001
Withdrew: Lost to follow-up0000000000000000000010000
Withdrew: Other0000000011000000000000110
Withdrew: Medication prohibited by protocol0000000000000000000000010
Withdrew: Death0000000000000000000000001

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) of TAK-117

MTD is highest dose level of TAK-117 at which no more than 1 out of 6 participants had a dose limiting toxicity (DLT) during first cycle. DLT was any 1 of following events occurring within first 21 days of Cycle 1 of TAK-117 administration, Grade 2: fasting hyperglycemia for \>14 days. Grade 3: nausea and/or vomiting/diarrhea for \>7 days; rash for \>7 days; thrombocytopenia with bleeding; fasting hyperglycemia for \>24 hours(hr). Grade \>=3:nonhematologic toxicity considered clinically significant by investigator. Grade 4:neutropenia (absolute neutrophil count \<=0.5\*10\^9per liter\[/L\]) for \>7 days in absence of growth factor support; neutropenia of any duration accompanied with fever \>=38.5 degree Celsius and/or systemic infection. Grade \>=4:hematologic toxicity. Inability to administer at least 75% of planned doses of TAK-117 within Cycle 1 due to its related toxicity;Any clinically significant occurrence that investigators and sponsor agreed would place participants at undue safety risk.

Time frame:
Baseline up to Cycle 1 Day 21
Reported as:
Number · mg
Maximum Tolerated Dose (MTD) of TAK-117
mgProcess A: Total QD TAK-117 100-300 mgProcess A: Total MWF QW 200-1200 mgProcess A: Total MTW QW 200-900 mgProcess B: Total FM MWF QW TAK-117 600-1200 mgProcess B: Total FM MTW QW 600-1500 mgProcess B: Total FM BID MWF QW 300-600 mg
Maximum Tolerated Dose (MTD) of TAK-117150900900NANA500
PrimaryNumber of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Death, Adverse Events (AEs) Leading to Discontinuation of Study Drug, and DLTs in Cycle 1
Time frame:
Baseline up to Cycle 27 Day 45
Reported as:
Number · participants
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Death, Adverse Events (AEs) Leading to Discontinuation of Study Drug, and DLTs in Cycle 1
participantsProcess A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QW
TEAE6684333312333311337333634107
SAE2342020252010712211121155
AEs leading to discontinuation of study drug1201000011010201001101014
Death0120010110000001000101101
DLTs in Cycle 10011000022000100100010001
PrimaryNumber of Participants With Highest Level of TEAEs Severity

Severity of AEs was evaluated based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0 as follow: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (life-threatening); Grade 5 (fatal).

Time frame:
Baseline up to Cycle 27 Day 45
Reported as:
Number · participants
Number of Participants With Highest Level of TEAEs Severity
participantsProcess A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QW
Grade 11000200010000000101100000
Grade 23421122250222111330031141
Grade 32131001053111711302131234
Grade 40012000000000310000000031
Grade 50120010110000001000101101
PrimaryNumber of Participants With Clinically Meaningful Changes in Laboratory Values
Time frame:
Baseline up to Cycle 27 Day 45
Reported as:
Number · participants
Number of Participants With Clinically Meaningful Changes in Laboratory Values
participantsProcess A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QW
Number of Participants With Clinically Meaningful Changes in Laboratory Values0000000000000000000000000
PrimaryNumber of Participants With Clinically Meaningful Changes in Vital Signs
Time frame:
Baseline up to Cycle 27 day 45
Reported as:
Number · participants
Number of Participants With Clinically Meaningful Changes in Vital Signs
participantsProcess A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QW
Number of Participants With Clinically Meaningful Changes in Vital Signs0000000000000000000000000
PrimaryNumber of Participants With Clinically Meaningful Changes in Electrocardiogram (ECG)
Time frame:
Baseline up to Cycle 27 Day 45
Reported as:
Number · participants
Number of Participants With Clinically Meaningful Changes in Electrocardiogram (ECG)
participantsProcess A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QW
Number of Participants With Clinically Meaningful Changes in Electrocardiogram (ECG)0000000000000000000000000
SecondaryOverall Response Rate (ORR)

The estimate of the ORR is calculated as crude percentage of participants who's best overall response is complete response (CR) or partial response (PR). Objective response (CR and PR) as determined by the participants best tumor response was assessed using response evaluation criteria in solid tumors (RECIST) version 1.1. As per RECIST version 1.1, CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 millimeter \[mm\]). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease was defined as not qualifying for CR, PR, and progressive disease (PD).

Time frame:
Cycle 1 Day 8 up to Cycle 27 Day 1 or disease progression or death
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsProcess A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QW
Overall Response Rate (ORR)0 (0.00 to 60.24)0 (0.00 to 45.93)13 (0.32 to 52.65)100 (15.81 to 100.00)0 (0.00 to 70.76)0 (0.00 to 70.76)0 (0.00 to 70.76)0 (0.00 to 70.76)0 (0.00 to 30.85)0 (0.00 to 70.76)0 (0.00 to 70.76)0 (0.00 to 70.76)0 (0.00 to 97.50)0 (0.00 to 33.63)0 (0.00 to 70.76)0 (0.00 to 97.50)0 (0.00 to 52.18)0 (0.00 to 70.76)0 (0.00 to 84.19)0 (0.00 to 70.76)0 (0.00 to 52.18)0 (0.00 to 70.76)0 (0.00 to 70.76)0 (0.00 to 36.94)25 (0.63 to 80.59)
SecondaryDuration of Objective Response

Duration of response was to be calculated for participants who achieved CR or PR. Duration of objective response was defined as the number of days from the start date of PR or CR (whichever response was achieved first) to the first date that PD or disease progression was objectively documented. The duration of objective response was to be right-censored for participants who achieved CR or PR and met 1 of the following conditions: Non-protocol anticancer treatment started before documentation of PD; Documented PD after more than 1 missed disease assessment visit; Alive and did not have documentation of PD before a data analysis cutoff date.

Time frame:
Cycle 1 Day 8 up to Cycle 27 Day 1 or disease progression or death

No measurements were reported for this outcome.

SecondaryClinical Benefit Rate (CBR)

Clinical benefit rate was defined as the participants who achieved stable disease (SD) for at least 15 weeks, CR, or PR. The estimate of the CBR was calculated as crude percentage of participants whose best ORR was CR, PR or SD for at least 90 days.

Time frame:
Cycle 1 Day 8 up to Cycle 27 Day 1 or disease progression or death
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR)
percentage of participantsProcess A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QW
Clinical Benefit Rate (CBR)25 (0.63 to 80.59)17 (0.42 to 64.12)38 (8.52 to 75.51)100 (15.81 to 100.00)33 (0.84 to 90.57)33 (0.84 to 90.57)33 (0.84 to 90.57)0 (0.00 to 70.76)20 (2.52 to 55.61)67 (9.43 to 99.16)0 (0.00 to 70.76)0 (0.00 to 70.76)0 (0.00 to 97.50)56 (21.20 to 86.30)33 (0.84 to 90.57)0 (0.00 to 97.50)0 (0.00 to 52.18)33 (0.84 to 90.57)0 (0.00 to 84.19)0 (0.00 to 70.76)0 (0.00 to 52.18)0 (0.00 to 70.76)33 (0.84 to 90.57)25 (3.19 to 65.09)25 (0.63 to 80.59)
SecondaryCmax: Maximum Observed Plasma Concentration for TAK-117
Time frame:
Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for TAK-117
nanogram per milliliter (ng/mL)Process A: TAK-117 100 mgProcess A: TAK-117 150 mgProcess A: TAK-117 200 mgProcess A: TAK-117 300 mgProcess A: TAK-117 400 mgProcess A: TAK-117 600 mgProcess A: TAK-117 900 mgProcess A: TAK-117 1200 mgProcess B: TAK-117 300 mgProcess B: TAK-117 400 mgProcess B: TAK-117 500 mgProcess B: TAK-117 600 mgProcess B: TAK-117 900 mgProcess B: TAK-117 1200 mgProcess B: TAK-117 1500 mg
Cmax: Maximum Observed Plasma Concentration for TAK-1171747.61 ± 48.71613.23 ± 58.52736.60 ± 36.42658.23 ± 90.04335.88 ± 42.54175.13 ± 82.47863.36 ± 42.18586.50 ± 53.61162.06 ± 117.51656.71 ± 77.02973.26 ± 53.33870.43 ± 61.16960.06 ± 69.36073.55 ± 53.26899.80 ± 67.9
SecondaryCtrough: Observed Concentration at the End of Dosing Interval for TAK-117
Time frame:
Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
Reported as:
Geometric mean · ng/mL
Ctrough: Observed Concentration at the End of Dosing Interval for TAK-117
ng/mLProcess A: TAK-117 100 mgProcess A: TAK-117 150 mgProcess A: TAK-117 200 mgProcess A: TAK-117 300 mgProcess A: TAK-117 400 mgProcess A: TAK-117 600 mgProcess A: TAK-117 900 mgProcess A: TAK-117 1200 mgProcess B: TAK-117 300 mgProcess B: TAK-117 400 mgProcess B: TAK-117 500 mgProcess B: TAK-117 600 mgProcess B: TAK-117 900 mgProcess B: TAK-117 1200 mgProcess B: TAK-117 1500 mg
Ctrough: Observed Concentration at the End of Dosing Interval for TAK-117187.29 ± 102.1177.70 ± 124.0630.82 ± 70.0627.62 ± 93.7NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
SecondaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-117
Time frame:
Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
Reported as:
Median · hr
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-117
hrProcess A: TAK-117 100 mgProcess A: TAK-117 150 mgProcess A: TAK-117 200 mgProcess A: TAK-117 300 mgProcess A: TAK-117 400 mgProcess A: TAK-117 600 mgProcess A: TAK-117 900 mgProcess A: TAK-117 1200 mgProcess B: TAK-117 300 mgProcess B: TAK-117 400 mgProcess B: TAK-117 500 mgProcess B: TAK-117 600 mgProcess B: TAK-117 900 mgProcess B: TAK-117 1200 mgProcess B: TAK-117 1500 mg
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-1171.5 (1 to 4)1.5 (1 to 2)2.0 (1 to 4)2.1 (1 to 4)4.0 (1 to 8)3.1 (1 to 4)2.0 (1 to 8)5.8 (4 to 8)1.6 (1 to 4)4.0 (2 to 8)3.6 (2 to 6)3.4 (1 to 8)4.0 (1 to 8)4.0 (1 to 23)3.8 (2 to 8)
SecondaryT 1/2z: Terminal Disposition Phase Half-life for TAK-117
Time frame:
Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
Reported as:
Mean · hrs
T 1/2z: Terminal Disposition Phase Half-life for TAK-117
hrsProcess A: TAK-117 100 mgProcess A: TAK-117 150 mgProcess A: TAK-117 200 mgProcess A: TAK-117 300 mgProcess A: TAK-117 400 mgProcess A: TAK-117 600 mgProcess A: TAK-117 900 mgProcess A: TAK-117 1200 mgProcess B: TAK-117 300 mgProcess B: TAK-117 400 mgProcess B: TAK-117 500 mgProcess B: TAK-117 600 mgProcess B: TAK-117 900 mgProcess B: TAK-117 1200 mgProcess B: TAK-117 1500 mg
T 1/2z: Terminal Disposition Phase Half-life for TAK-1178.74 ± 3.07.32 ± 3.311.17 ± 4.59.75 ± 5.512.24 ± 3.914.71 ± 6.411.12 ± 3.925.87 ± 22.7NA ± NANA ± NANA ± NA12.17 ± 4.08.34 ± 4.714.28 ± 3.59.53 ± 2.5
SecondaryAUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-117
Time frame:
Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
Reported as:
Geometric mean · nanogram hours per milliliter (ng*hr/mL)
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-117
nanogram hours per milliliter (ng*hr/mL)Process A: TAK-117 100 mgProcess A: TAK-117 150 mgProcess A: TAK-117 200 mgProcess A: TAK-117 300 mgProcess A: TAK-117 400 mgProcess A: TAK-117 600 mgProcess A: TAK-117 900 mgProcess A: TAK-117 1200 mgProcess B: TAK-117 300 mgProcess B: TAK-117 400 mgProcess B: TAK-117 500 mgProcess B: TAK-117 600 mgProcess B: TAK-117 900 mgProcess B: TAK-117 1200 mgProcess B: TAK-117 1500 mg
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-11718008 ± 78.813807 ± 93.244733 ± 58.042909 ± 102.293748 ± 19.875937 ± 94.4129217 ± 56.0309073 ± 23.7NA ± NANA ± NANA ± NA62876 ± 78.484394 ± 103.1164508 ± 74.987515 ± 81.2
SecondaryAUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-117
Time frame:
Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose

No measurements were reported for this outcome.

Secondary%AUC Extrapolated: Percentage of Area Under Concentration-extrapolated
Time frame:
Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose

No measurements were reported for this outcome.

SecondaryPercent Change From Baseline in Pharmacodynamic Markers

Pharmacodynamic markers included phosphorylated ribosomal protein S6 (PS6), phosphorylated eukaryotic initiation factor 4E-binding protein 1 (P4EBP1), phosphorylated N-myc downstream regulated gene 1 (PNDRG1), phosphorylated proline-rich AKT substrate of 40 kilodaltons (PPRAS40), and phosphorylated serine/threonine protein kinase AKT (PAKT). Analysis population (n) for each skin biopsy biomarker is as follow: P4EBP1 (n=6,6,6,2,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PAKT and PNDRG1 (n=6,6,7,2,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PPRAS40 (n= 6,0,6,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PS6 (n=6,6,7,2,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0)."n" for each tumor tissue biomarkers is as follow: P4EBP1, PAKT, PNDRG1, and PS6 (n=1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PPRAS40 (n= 1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0).

Time frame:
Cycle 1 Day 8
Reported as:
Mean · percent change
Percent Change From Baseline in Pharmacodynamic Markers
percent changeProcess A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QW
Skin Biopsy: P4EBP1-27.94 ± 56.666-13.07 ± 39.758-61.41 ± 40.015-24.50 ± 54.388-100.00 ± 0.000NA ± NANA ± NANA ± NANA ± NA-100.00 ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Skin Biopsy: PAKT-11.59 ± 33.833190.32 ± 257.212-30.02 ± 37.444-12.97 ± 5.896-18.75 ± 26.517NA ± NANA ± NANA ± NANA ± NA733.33 ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Skin Biopsy: PNDRG1-9.82 ± 15.138-0.11 ± 35.915-10.11 ± 26.814-21.67 ± 35.35510.69 ± 31.283NA ± NANA ± NANA ± NANA ± NA-34.44 ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Skin Biopsy: PPRAS4069.56 ± 272.327NA ± NA-26.90 ± 37.191-18.75 ± 61.872-14.17 ± 8.250NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Skin Biopsy: PS6-15.23 ± 18.886-25.05 ± 15.883-11.88 ± 37.77322.70 ± 24.4629.54 ± 19.146NA ± NANA ± NANA ± NANA ± NA46.15 ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Tumor Tissue: P4EBP1236.00 ± NA-97.56 ± NANA ± NANA ± NA7.48 ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Tumor Tissue: PAKT850.00 ± NA-20.87 ± NANA ± NANA ± NA-44.83 ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Tumor Tissue: PNDRG1134.69 ± NA-16.49 ± NANA ± NANA ± NA134.29 ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Tumor Tissue: PPRAS40196.83 ± NANA ± NANA ± NANA ± NA10.43 ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Tumor Tissue: PS6200.00 ± NA0.00 ± NANA ± NANA ± NA-82.86 ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Process A: TAK-117 100 Milligram (mg), Once Daily (QD)—2/6 (33.3%)6/6 (100%)
Process A: TAK-117 150 mg, QD—3/6 (50%)6/6 (100%)
Process A: TAK-117 200 mg, QD—4/8 (50%)8/8 (100%)
Process A: TAK-117 300 mg, QD—2/4 (50%)4/4 (100%)
Process A: TAK-117 200 mg, MWF QW—0/3 (0%)3/3 (100%)
Process A: TAK-117 300 mg, MWF QW—2/3 (66.7%)3/3 (100%)
Process A: TAK-117 400 mg, MWF QW—0/3 (0%)3/3 (100%)
Process A: TAK-117 600 mg, MWF QW—2/3 (66.7%)3/3 (100%)
Process A: TAK-117 900 mg, MWF QW—5/12 (41.7%)12/12 (100%)
Process A: TAK-117 1200 mg, MWF QW—2/3 (66.7%)3/3 (100%)
Process A: TAK-117 200 mg, MTW QW—0/3 (0%)3/3 (100%)
Process A: TAK-117 400 mg, MTW QW—1/3 (33.3%)3/3 (100%)
Process A: TAK-117 600 mg, MTW QW—0/3 (0%)3/3 (100%)
Process A: TAK-117 900 mg, MTW QW—7/11 (63.6%)11/11 (100%)
Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW—1/3 (33.3%)3/3 (100%)
Process B: TAK-117 900 mg FM MWF QW—2/3 (66.7%)3/3 (100%)
Process B: TAK-117 1200 mg FM MWF QW—2/7 (28.6%)7/7 (100%)
Process B: TAK-117 600 mg FM MTW QW—1/3 (33.3%)3/3 (100%)
Process B: TAK-117 900 mg FM MTW QW—1/3 (33.3%)3/3 (100%)
Process B: TAK-117 1200 mg FM MTW QW—1/3 (33.3%)3/3 (100%)
Process B: TAK-117 1500 mg FM MTW QW—2/6 (33.3%)6/6 (100%)
Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW—1/4 (25%)2/4 (50%)
Process B: TAK-117 400 mg FM BID MWF QW—1/4 (25%)4/4 (100%)
Process B: TAK-117 500 mg FM BID MWF QW—5/10 (50%)10/10 (100%)
Process B: TAK-117 600 mg FM BID MWF QW—5/8 (62.5%)7/8 (87.5%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventProcess A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QW
VomitingGastrointestinal disorders1/60/60/80/40/30/30/31/30/121/30/30/30/30/110/30/30/70/31/30/30/60/40/40/101/8
NauseaGastrointestinal disorders1/60/60/80/40/30/30/30/30/121/30/30/30/30/110/30/30/70/30/30/31/60/40/40/100/8
DiarrhoeaGastrointestinal disorders0/60/60/80/40/30/30/31/30/121/30/30/30/30/110/30/30/70/30/30/30/60/40/40/100/8
ColitisGastrointestinal disorders0/60/60/80/40/30/30/30/30/120/30/30/30/30/110/30/30/71/30/30/30/60/40/40/100/8
Upper gastrointestinal haemorrhageGastrointestinal disorders0/60/60/80/40/30/30/30/30/120/30/30/30/30/111/30/30/70/30/30/30/60/40/40/100/8
Respiratory failureRespiratory, thoracic and mediastinal disorders0/60/60/81/40/31/30/31/31/120/30/30/30/30/110/30/30/70/30/30/30/60/40/40/100/8
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/60/60/80/40/30/30/30/30/121/30/30/30/30/110/30/31/70/30/30/30/60/40/40/100/8
CellulitisInfections and infestations0/60/60/80/40/31/30/30/30/120/30/30/30/30/110/30/30/70/30/30/30/60/40/40/100/8
HyperglycaemiaMetabolism and nutrition disorders0/60/60/80/40/30/30/30/30/121/30/30/30/30/110/30/31/70/30/30/30/60/40/42/100/8
DehydrationMetabolism and nutrition disorders0/60/60/80/40/30/30/30/30/121/30/30/30/30/110/30/30/70/30/30/30/60/40/40/100/8
Most frequent other events
Showing 10 of 263
Most frequent other events
EventProcess A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QW
NauseaGastrointestinal disorders3/64/65/82/41/32/30/33/38/121/32/32/31/310/112/31/36/71/32/32/34/62/42/47/103/8
StomatitisGastrointestinal disorders0/61/61/80/41/30/30/30/31/121/30/30/30/31/111/30/31/71/31/33/31/60/40/41/102/8
FatigueGeneral disorders1/66/64/81/41/32/31/30/37/121/33/31/30/36/110/32/33/72/32/33/35/61/41/46/102/8
DiarrhoeaGastrointestinal disorders1/63/65/83/40/31/32/31/36/121/30/30/32/38/110/32/35/70/31/31/34/62/42/43/103/8
Decreased appetiteMetabolism and nutrition disorders1/61/64/82/41/32/31/32/32/122/31/31/30/34/110/31/34/71/30/31/33/61/43/46/101/8
Aspartate aminotransferase increasedInvestigations1/63/64/83/42/32/31/30/34/121/31/30/31/32/111/30/30/71/31/32/32/61/41/41/103/8
Alanine aminotransferase increasedInvestigations1/62/63/83/41/31/31/30/33/121/30/30/31/32/111/30/30/70/31/31/32/61/41/41/104/8
VomitingGastrointestinal disorders2/61/64/81/42/32/30/32/38/122/32/31/32/37/110/32/35/71/32/30/34/62/41/47/105/8
ConstipationGastrointestinal disorders1/64/63/81/41/30/31/32/34/121/31/31/30/34/110/30/32/71/31/32/32/60/42/41/100/8
HyperglycaemiaMetabolism and nutrition disorders3/60/62/82/42/31/31/30/34/122/31/31/31/36/112/30/32/71/31/30/33/61/42/45/102/8

Baseline characteristics

The all subjects as treated (ASaT) population included all enrolled participants who received at least 1 dose of TAK-117.

Age, Continuous
Age, Continuous(years)Process A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QWTotal
Mean64.7 ± 9.7959.0 ± 10.8859.3 ± 9.0545.3 ± 7.2756.3 ± 17.6752.7 ± 14.0154.3 ± 12.5865.0 ± 13.1156.4 ± 13.2853.3 ± 19.4064.7 ± 18.5850.0 ± 11.5355.0 ± 9.5457.4 ± 10.8865.7 ± 12.8662.7 ± 16.1761.0 ± 11.8952.7 ± 19.7653.7 ± 1.5366.7 ± 2.5261.3 ± 13.6872.5 ± 4.6560.3 ± 11.8166.0 ± 8.7159.5 ± 10.3959.4 ± 11.89
Gender
Gender(Participants)Process A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QWTotal
Female445322239311371151224445684
Male223111103022042222112005241
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Process A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QWTotal
Hispanic or Latino00000000000000000000000112
Not Hispanic or Latino566433231133231133733364497117
Unknown or Not Reported10200010100100000000000006
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Process A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QWTotal
White6683321312331311227333633108115
Black or African American00000100000100010000001004
Asian00010010000100000000000003
Other00000000000000100000010002
Not Reported00000010000000000000000001
Female Child Bearing Potential
Female Child Bearing Potential(participants)Process A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QWTotal
Females of Child-bearing Potential00111000100100000000001107
Post-menopausal433011114200220141214433451
Sterilized Females011201124110151010010001226
Males (Excluded from this analysis)223111103022042222112005241
Height
Height(centimeter (cm))Process A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QWTotal
Mean161.70 ± 10.758164.29 ± 7.241165.25 ± 9.403164.15 ± 5.837164.19 ± 5.195161.81 ± 5.222165.17 ± 7.848163.49 ± 6.883163.08 ± 12.871158.76 ± 9.161168.76 ± 2.043173.43 ± 6.072164.67 ± 3.055167.46 ± 10.274170.22 ± 1.683168.93 ± 16.176168.32 ± 4.243169.83 ± 13.829169.52 ± 8.713168.11 ± 6.887165.97 ± 6.472159.00 ± 3.939157.05 ± 3.316168.79 ± 13.186164.87 ± 9.638165.49 ± 9.098
Weight
Weight(kilogram (kg))Process A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QWTotal
Mean62.18 ± 6.40371.15 ± 21.86273.48 ± 9.15967.65 ± 24.51372.48 ± 17.66561.54 ± 2.48757.73 ± 0.46263.41 ± 3.88069.14 ± 15.48665.03 ± 15.13770.76 ± 16.45883.39 ± 28.85260.60 ± 9.01673.78 ± 12.95572.26 ± 11.23575.22 ± 12.67979.84 ± 16.64881.07 ± 25.41782.72 ± 17.98262.61 ± 15.70664.59 ± 16.47773.65 ± 16.74765.37 ± 11.85370.51 ± 15.26365.11 ± 9.59970.17 ± 14.958
Body Surface Area (BSA)
Body Surface Area (BSA)(square meter (m^2))Process A: TAK-117 100 Milligram (mg), Once Daily (QD)Process A: TAK-117 150 mg, QDProcess A: TAK-117 200 mg, QDProcess A: TAK-117 300 mg, QDProcess A: TAK-117 200 mg, MWF QWProcess A: TAK-117 300 mg, MWF QWProcess A: TAK-117 400 mg, MWF QWProcess A: TAK-117 600 mg, MWF QWProcess A: TAK-117 900 mg, MWF QWProcess A: TAK-117 1200 mg, MWF QWProcess A: TAK-117 200 mg, MTW QWProcess A: TAK-117 400 mg, MTW QWProcess A: TAK-117 600 mg, MTW QWProcess A: TAK-117 900 mg, MTW QWProcess B: TAK-117 600 mg Process B Capsule (FM) MWF QWProcess B: TAK-117 900 mg FM MWF QWProcess B: TAK-117 1200 mg FM MWF QWProcess B: TAK-117 600 mg FM MTW QWProcess B: TAK-117 900 mg FM MTW QWProcess B: TAK-117 1200 mg FM MTW QWProcess B: TAK-117 1500 mg FM MTW QWProcess B: TAK-117 300 mg FM Twice Daily (BID) MWF QWProcess B: TAK-117 400 mg FM BID MWF QWProcess B: TAK-117 500 mg FM BID MWF QWProcess B: TAK-117 600 mg FM BID MWF QWTotal
Mean1.67 ± 0.1081.78 ± 0.2661.83 ± 0.1521.85 ± 0.5001.81 ± 0.2411.66 ± 0.0601.63 ± 0.0411.70 ± 0.0631.76 ± 0.2481.69 ± 0.1921.81 ± 0.2091.99 ± 0.3541.66 ± 0.1101.85 ± 0.2141.85 ± 0.1511.88 ± 0.2351.92 ± 0.2101.95 ± 0.3841.97 ± 0.2621.70 ± 0.2501.72 ± 0.2531.80 ± 0.2171.68 ± 0.1541.82 ± 0.2561.71 ± 0.1701.79 ± 0.219
08

Study locations

5 sites
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Dallas, Texas, United States
  • Barcelona, Spain
  • Sutton, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jul 2015 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2011
First posted
Oct 10, 2011
Start
Oct 2011
Primary completionActual
Jul 2015
CompletionActual
Jan 2016
Results first posted
Mar 9, 2017
Last update
Mar 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01449370
Responsible party
Sponsor
First posted
Oct 10, 2011
Start date
Oct 2011
Primary completion
Jul 2015
Completion
Jan 2016
Results posted
Mar 9, 2017
Last update
Mar 9, 2017

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serabelisib

Start the discussion